Eczema

Hui addresses one of the NEA's Eczema Awareness Month weekly themes, "Eczema is more than the visuals."

AbbVie's Eczema Experience Pop-Up event recently provided attendees with immersive insights into the physical and psychosocial toll associated with eczema.

Researchers behind the review suggested that future research should prioritize large-scale trials to confirm abrocitinib's long-term safety and efficacy in various skin disorders.

Announcements from both the FDA and the EC were supported by 2 clinical trials that evaluated the safety and efficacy of delgocitinib cream.

Catch up on eczema advancements throughout the year, including news on contact dermatitis, chronic hand eczema, and more.

During an interview with Dermatology Times, Zirwas outlined modern allergens such as sulfites, dietary nickel, and acrylates.

The data was presented at the European Society of Contact Dermatitis in Dresden, Germany, this week.

Chronic hand eczema patients with high corticosteroid phobia are less likely to follow prescribed treatments, indicating a need for improved education.

Participants experienced improvements with both glove types, though cotton gloves were generally preferred for comfort and Sympatex for tactile sensitivity.

In this episode, Vikash Oza, MD, and James Treat, MD, discuss their SPD 2024 session (debate) revolving around the topic: Does food trigger eczema?

Raj Chovatiya, MD, PhD, reviews the varying degrees of influence of skin barrier disruption, immune dysregulation, and Malassezia yeast in seborrheic dermatitis.

Chovatiya was a lead author of the latest seborrheic dermatitis and roflumilast foam review published in the Journal of Clinical and Aesthetic Dermatology.

At present, deployed members of the military are not permitted to be receiving therapy with systemic therapies such as immunomodulators and biologics.

The data was presented in a scientific session at the American Academy of Dermatology annual meeting.

Melinda Gooderham, MSc, MD, FRCPC, provided insights into the significance of the DELTA 3 extension data presented at AAD 2024.

In a recent study, topical ruxolitinib improved clinical outcomes, itch, and patient quality of life.

Patients treated with the ointment showed improvement in lesional percentage body surface area.

Both cream options were capable of reducing scores of itching, drying, burning, redness, and more.

Dermatologists Jeanine Downie, DiAnne Davis, and Hope Mitchell reveal the La Roche-Posay products they recommend to patients with dry skin, eczema, and more, at the flagship store in France.

An OTC moisturizer was found to improve skin ceramide levels in patients with eczema-prone skin.

Zoryve was approved for the treatment of seborrheic dermatitis in patients ages 9 years and older in December.

In a recent study, prenatal opioid exposure was also linked to increased odds of infections and asthma, but not with allergies, anaphylaxis, orautoimmune conditions.

Data from Arcutis’ STRATUM study was presented at the 2024 Winter Clinical Hawaii Dermatology Conference.

Ten posters at the Winter Clinical Hawaii and Maui Derm Conferences will showcase investigational data to expand treatment options for patients with atopic dermatitis and chronic hand eczema.